GLP-1 drugs work even without weight loss — and scientists are finally mapping why

Key Findings

🫘 Semaglutide Just Scored a Major Kidney Win

• A pooled analysis of three large randomized trials — SELECT, FLOW, and SOUL — found that semaglutide consistently reduced serious kidney outcomes across diverse patient populations, including those with obesity but without type 2 diabetes.
• The finding strengthens the case that kidney protection is a genuine drug effect, not a side effect of better blood sugar control.

🧠 These Drugs Are Rewiring the Brain — Literally

• A Cell Metabolism Voices piece highlights growing evidence that GLP-1 drugs act primarily through central and peripheral neural circuits to regulate energy balance, not just through gut signaling.
• Researchers are now asking which specific brain pathways to target next — and whether hitting them more precisely could improve efficacy while reducing nausea.

💊 Tirzepatide Cuts Heart Attack Risk in the Real World

• A population-based cohort study in the BMJ found that adding tirzepatide to standard care was associated with a meaningful reduction in major adverse cardiovascular events in clinical practice — not just in controlled trial conditions.
• The result matters because real-world patients are messier than trial participants: more comorbidities, less adherence, more variation in dosing.

🍺 Semaglutide Reduced Heavy Drinking Days in a Clinical Trial

• In adults with alcohol use disorder and comorbid obesity, weekly semaglutide was associated with fewer heavy drinking days at 26 weeks compared to placebo.
• The finding adds to a growing pile of signals suggesting GLP-1 drugs may blunt addictive behaviors — though the mechanism remains under investigation.

🦴 Weight Loss From These Drugs Comes With a Muscle Trade-Off

• Across incretin-based therapies, roughly 25–39% of total weight lost over 36–72 weeks appears to come from lean body mass, not fat — a concern that is rarely tracked in clinical practice.
• A review in Cardiorenal Medicine argues that muscle loss in high-risk patients could accelerate frailty and undermine the very cardiovascular and kidney gains the drugs are supposed to deliver.

👁️ A Rare Vision Risk Is Getting Harder to Ignore

• Emerging pharmacovigilance data and case reports link semaglutide to a rare but serious condition called non-arteritic anterior ischemic optic neuropathy (NAION) — sudden vision loss caused by reduced blood flow to the optic nerve.
• A new case report proposes a 'two-hit' model: anatomical vulnerability in the eye plus drug-related dehydration may together trigger the event, though causality has not been established.